Next-Generation Obesity Therapy: Amylin Analog Gains Momentum

As the obesity and diabetes treatment market rapidly expands, Zealand Pharma and Roche's Amylin Analog 'Petrelintide' is gaining attention as a promising new therapy. Unlike existing GLP-1 (Glucagon-Like Peptide-1) receptor agonists, Amylin Analog mimics the hormone Amylin secreted by the pancreas to induce satiety and regulate gastric emptying. Recent Phase 2 'ZUPREME-1' trial results have firmly demonstrated the drug's efficacy, positioning it as a new alternative for patients who have grown weary of gastrointestinal side effects from current treatments.

Outstanding Weight Loss Efficacy and Exceptional Tolerability

The Phase 2 trial involved 493 patients with overweight and obesity, who received weekly doses of Petrelintide over 42 weeks. The high-dose group achieved an average weight loss of 10.7%, significantly outperforming the placebo group (1.7%). Notably, the drug demonstrated tolerability comparable to placebo, with very few cases of treatment discontinuation due to gastrointestinal side effects such as nausea or vomiting. This suggests the potential to significantly reduce the number of patients who discontinue therapy due to adverse effects.

Background of Roche's $530 Million Mega Deal with Zealand Pharma

Based on these impressive clinical results, Zealand Pharma entered into a $530 million partnership and licensing agreement with global pharmaceutical company Roche in March 2025. Roche's upfront payment of $1.65 billion reflects its extremely high evaluation of Petrelintide's commercial potential. Roche aims to secure a dominant position in the obesity treatment market by combining Petrelintide with its existing GLP-1/GIP dual-acting agent 'CT-388'. This move highlights the strong intent of global big pharma to maximize synergies beyond the limitations of single mechanisms.

Phase 3 Trial Entry in 2026 and Market Shift on Horizon

Building on the success of the Phase 2 trial, the two companies have officially announced plans to enter a large-scale Phase 3 trial in the second half of 2026. Petrelintide is expected to directly compete with Novo Nordisk's Cagrilintide and Eli Lilly's Eloralintide in the obesity treatment market, which is projected to grow to approximately $130 billion by the early 2030s. In particular, the Amylin monotherapy and combination therapy with fewer gastrointestinal side effects are likely to attract a large number of patients who do not respond to or experience side effects from GLP-1 treatments. The global competition for leadership in the next-generation metabolic disease market is expected to intensify further.